Table 3.
Numbers of embryos with good quality (GQE) or top quality (TQE) from patients treated with GnRH agonists depending on the day of morphology assessment.
| Day | Protocol | GQE [n/n (total) (%)] | p* | TQE (n/n (total) (%)] | p* |
|---|---|---|---|---|---|
| 2 | GnRH agonist | 116/172 (67.4%) | 0.342 | 60/170 (35.3%) | 0.820 |
| GnRH antagonist | 118/163 (72.4%) | 60/163 (36.8%) | |||
| 3 | GnRH agonist | 92/165 (55.8%) | 0.819 | 51/165 (30.9%) | 0.716 |
| GnRH antagonist | 84/146 (57.5%) | 48/146 (32.9%) | |||
| 4 | GnRH agonist | 78/143 (54.5%) | 0.624 | 46/143 (32.2%) | 1.000 |
| GnRH antagonist | 72/125 (57.6%) | 41/125 (32.8%) | |||
| 5 | GnRH agonist | 22/80 (27.5%) | 0.514 | 17/80 (21.3%) | 0.720 |
| GnRH antagonist | 31/96 (32.3%) | 23/96 (24.0%) | |||
| Final day | GnRH agonist | 61/172 (35.5%) | 0.734 | 28/170 (16.5%) | 1.000 |
| GnRH antagonist | 61/163 (37.4%) | 27/163 (16.6%) |
*
Fisher's exact test (2-sided).